University of Toronto
Toronto General Hospital
His laboratory has taken a multipronged approach to understand inherited predisposition to colorectal and pancreas cancer. First, large population based registries have been developed using incident cases in Ontario identified by the Ontario Cancer Registry at Cancer Care Ontario from 1997 to the present (the Ontario Familial Colorectal Cancer Registry and the Ontario Pancreas Cancer Study). Family history and epidemiologic questionnaires have been administered to these subjects and biospecimens (including blood and tumors) banked at the Biospecimen Repository at Mount Sinai Hospital. These registries have been supplemented by clinic-based cases enrolled through the HPB program at UHN and the Zane Cohen Digestive Diseases Centre at Mount Sinai Hospital where he is co-Director. Second, knockout mouse models have been used to characterise both germline and somatic mutational events during colorectal tumorigenesis, and to study chemopreventive agents including COX-2 inhibitors. A third and recent set of studies includes characterising germline genomic copy number variation as a novel mechanism underlying human phenotypic variation, including susceptibility to cancer.
Dr. Gallinger is also Head of the Hepatobiliary/pancreatic surgical oncology program at Mount Sinai Hospital and UHN, and Chair of the CCO HPB surgical oncology working group which is implementing volume/outcome based principles to standardise guidelines for HPB surgical oncology care in Ontario.